Equity Details
Price & Market Data
Price: $23.15
Daily Change: -$0.51 / 2.20%
Daily Range: $22.96 - $23.61
Market Cap: $2,990,456,320
Daily Volume: 602,344
Performance Metrics
1 Week: -10.03%
1 Month: 4.40%
3 Months: -11.58%
6 Months: 398.1%
1 Year: 347.8%
YTD: 140.9%
About Alumis Inc. (ALMS)
Latest market trends for Alumis Inc. (ALMS). The stock is priced at 23.15, showing a daily shift of -$0.51 / 2.20%. Market cap: 2,990,456,320. All performance data is provided for your review.
Company Details
Employees: 224
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.